Skip to content
‹ Back to IndustriesHealthcare

From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation

The rapid advancement in oncology therapies is outpacing the healthcare system's ability to manage them, resulting in increased prior authorization and treatment denials. This article explores the potential of AI and clinical trials to alleviate these issues while emphasizing the necessity of human oversight. Experts discuss the impact on patient care and the opportunities to enhance access and reduce costs.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from PayerWatch on MarketScale.

By Payerwatch · · Ai in HealthcareBrian McgrawCancer Treatment DelaysClinical Trials Access
Share

Key takeaways

01

Oncology denials are financially and clinically impactful, delaying treatments.

02

AI can augment appeal processes but requires vigilant human oversight.

03

Clinical trials should be integrated earlier in patient care pathways to improve access.

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians spend nearly two business days per week on administrative tasks like authorizations, contributing significantly to burnout and delayed care.

So how can clinicians ensure patients receive timely, life-saving treatments in a system increasingly shaped by cost controls and automation? And more importantly—can AI become part of the solution rather than just a tool for denials?

On this episode of PayerWatch, host Brian McGraw is joined by Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical AI Officer of Massive Bio, and Dr. Kendall Smith, Chief Medical Officer and Chief Physician Advisor at PayerWatch, for a conversation about oncology denials, prior authorization burden, and the emerging role of AI in appeals and access. Together, they examine how payer decision-making affects cancer patients, why clinical trialsPay are often overlooked in denial workflows, and how human oversight must remain central as AI becomes more common on both sides of the claims equation.

Key Takeaways from the episode:

  • Oncology denials are uniquely high stakes. Expensive biologics, chemo regimens, and precision therapies are often subject to heavier scrutiny, creating delays that can worsen outcomes and increase financial toxicity for patients.
  • AI can help, but only with human oversight. The guests discuss how AI can support appeals, clinical trial matching, and documentation, while warning that hallucinated citations and unchecked outputs can undermine care decisions.
  • Clinical trials should be considered earlier, not later. Instead of treating trials as a last resort or administrative complication, the episode argues they should be more proactively presented as care options that may reduce costs and expand access.

Dr. Arturo Loaiza-Bonilla is a practicing medical oncologist and hematologist, as well as the Co-Founder and Chief Medical AI Officer of Massive Bio. He has spent years working at the intersection of oncology, patient access, and artificial intelligence, helping develop AI-driven tools that connect patients to clinical trials and treatment options. In the episode, he also references his leadership role in a large hematology-oncology network and his long-standing interest in applying data science and computational tools to real-world cancer care.

Dr. Kendall Smith serves as Chief Medical Officer and Chief Physician Advisor at PayerWatch, where he brings deep expertise in chemotherapy and biologic denials, appeals strategy, and payer-provider disputes. His contributions to the episode focus on the practical realities of appeal workflows, the risks and opportunities of AI-assisted case preparation, and the importance of maintaining a human-in-the-loop approach when patient lives are on the line.

Part of this channel

PayerWatch

News, updates, and expert insights from PayerWatch.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

P
Payerwatch
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Epic's seven bets beyond the EHR, sorted by when hospitals can actually use them

Epic's seven bets beyond the EHR, sorted by when hospitals can actually use them

Epic is expanding past its EHR into ERP, IT staffing, AI, drug pricing and payer technology. Delivery runs from tools live today to a full EpicOps rollout that may not arrive until 2029. The payer platform has the clearest proof point: St. Luke's and UnitedHealthcare automated status updates on 88% of the claims they exchanged.

  • 01Epic's payer platform is the expansion bet with a measured result: 88% of claim status updates automated between St. Luke's and UnitedHealthcare, plus a 25% drop in status calls.
  • 02EpicOps, Epic's ERP suite, may not be fully available until 2029, so a health system whose ERP commitments end sooner can test individual modules alongside its current system without a full switch.
  • 03Before buying any third-party app that has to work inside Epic, ask the vendor to demonstrate the exact write operation it needs in your own environment, because FHIR support alone does not guarantee write access.

Nov 16, 2026

Avanlee Care’s $3.5M seed tests whether Medicare Advantage plans will pay to reach caregivers

Avanlee Care’s $3.5M seed tests whether Medicare Advantage plans will pay to reach caregivers

Avanlee Care raised a $3.5 million seed round led by BEA Venture Fund, bringing total funding to $6 million. The startup helps Medicare Advantage plans find and support members' family caregivers. Its bet: plans will pay to reach whoever books the visits.

  • 01Medicare Advantage plans can see overdue visits and refills; Avanlee Care’s $3.5M seed backs a per-member-per-month model to reach the family caregiver who can act on that outreach.
  • 02Caregiver support among Medicare Advantage Special Needs Plans rose from 5% of plans in 2025 to 16% in 2026, even as meals and transportation benefits declined. That gives benefit designers a reference point.

Nov 15, 2026

Oura's $625 million Counsel Health deal puts a ring maker in the triage business

Oura's $625 million Counsel Health deal puts a ring maker in the triage business

Oura is buying Counsel Health for $625 million in cash, bringing an AI chat service with on-demand physicians in-house. Counsel will keep selling triage and virtual care to health plans, health systems and employers. Outcomes data is still to come.

  • 01For $625 million in cash, a smart ring company now owns a service pitched to health plans as a replacement for the nurse triage line.
  • 02Counsel's website offers a free conversation with Counsel AI and lets users add a doctor for $29, a public reference point benefits teams could use when comparing virtual care costs.
  • 03The evidence behind the combined model is member satisfaction (4.6 out of 5) and self-reported surveys; clinical outcomes and cost results are the numbers that would confirm it.

Nov 15, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

P
Payerwatch
DA
Dr. Arturo Loaiza-Bonilla

Co-Founder and Chief Medical AI Officer

Massive Bio

Dr. Arturo Loaiza-Bonilla is a practicing medical oncologist and hematologist. He is the Co-Founder and Chief Medical AI Officer at Massive Bio, where he focuses on integrating AI into cancer care.

DK
Dr. Kendall Smith

Chief Medical Officer and Chief Physician Advisor

PayerWatch

Dr. Kendall Smith serves as the Chief Medical Officer and Chief Physician Advisor at PayerWatch. He specializes in improving healthcare provider outcomes in response to payer denials.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512